Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Beatrice Ruffilli
Observed names:
B Ruffilli,
B. Ruffilli
Institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Azienda Ospedaliero Universitaria Maggiore della Carita
Observed institutions:
Università degli Studi del Piemonte Orientale “Amedeo Avogadro”,
Azienda Ospedaliero Universitaria Maggiore della Carita
ORCID:
0009-0007-8405-7256
Observed ORCID:
0009-0007-8405-7256
OpenAlex ID:
A5074385535
Early prediction of endocrine responsiveness in ER+/HER2-negative metastatic breast cancer (MBC): pilot study with 18F-fluoroestradiol (18F-FES) CT/PET
2024
·
A. Gennari
, E. Brain
, et al.
·
Annals of Oncology
·
34
PDF
Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management
2025
·
Simone Nardin
, Beatrice Ruffilli
, et al.
·
Cancers
·
21
PDF
Navigating Cardiotoxicity in Immune Checkpoint Inhibitors: From Diagnosis to Long-Term Management
2025
·
Simone Nardin
, Beatrice Ruffilli
, et al.
·
Journal of Cardiovascular Development and Disease
·
17
PDF
315P Real-world safety and effectiveness of T-DXd in older advanced breast cancer Patients: Updated analysis in an expanded cohort from the TREX-old registry
2025
·
A. Deleuze
, S. Nardin
, et al.
·
ESMO Open
·
2
PDF
Early prediction of endocrine responsiveness in ER+/HER2 negative MBC: Pilot study with 18F-fluoroestradiol (18F-FES) CT/PET.
2023
·
Alessandra Gennari
, Etienne Brain
, et al.
·
Journal of Clinical Oncology
·
2
Retrospective Trial on Cetuximab Plus Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Cancer
2025
·
Morena Fasano
, Francesco Perri
, et al.
·
Cancers
·
1
PDF
141P Circulating immune cells predict immunotherapy benefit in patients with triple negative breast cancer: Preliminary results from the IRIS study
2024
·
B. Conte
, V. Martini
, et al.
·
Annals of Oncology
·
1
PDF
Interimsanalyse zur erweiterten anti-hormonellen Therapie beim frühen, HR+/HER2- Mammakarzinom in München (D) und Novara (I) im Rahmen pflegebegleiteter Sprechstunden – CarEoTT
2026
·
F Henze
, B Ruffilli
, et al.
·
Senologie - Zeitschrift für Mammadiagnostik und -therapie
Abstract PS4-01-16: The transcriptomic profile of circulating T lymphocytes is associated with response to neoadjuvant therapy in patients with early breast cancer
2026
·
B. Conte
, S. D'Alfonso
, et al.
·
Clinical Cancer Research
Abstract PS2-10-14: Blood-based metabolomic profiling and transcriptomic analysis of circulating cd3+ t cells reveal associations with treatment response and immune activation in early breast cancer (ebc)
2026
·
V. Martini
, B. Conte
, et al.
·
Clinical Cancer Research
Abstract PS2-09-23: Preliminary Results from the NEOMET Trial: Nutritional and Exercise Interventions During Neoadjuvant Chemotherapy in Early Breast Cancer
2026
·
I. Taglialatela
, B. Conte
, et al.
·
Clinical Cancer Research
Abstract PS2-09-17: Comprehensive peripheral immune profiling in Triple Negative Breast Cancer (TNBC) links immune cell dynamics to therapeutic response and irAEs: insight from the IRIS Study
2026
·
L. Negrini
, V. Martini
, et al.
·
Clinical Cancer Research
339P Transcriptomic profiling of circulating T lymphocytes predicts response to neoadjuvant therapy in patients with early breast cancer
2025
·
B. Conte
, S. D'Alfonso
, et al.
·
Annals of Oncology
318P PD-L1+ tumoral extracellular vesicles as biomarkers of immune-related toxicities in TNBC: Preliminary results from the IRIS study
2025
·
T.L. Landolfo
, V. Martini
, et al.
·
Annals of Oncology
311P Exploring circulating MDSC role in immune-related adverse events (irAEs) in early triple-negative breast cancer (eTNBC): A preliminary analysis from the IRIS study
2025
·
I. Taglialatela
, L. Negrini
, et al.
·
Annals of Oncology
572P Molecular imaging with 18F-fluoroestradiol (18F-FES) to assess intrapatient heterogeneity in ER+/HER2- metastatic breast cancer (MBC) treated with first-line endocrine therapy: Final results of the ET-FES trial
2025
·
A. Gennari
, S. Nardin
, et al.
·
Annals of Oncology
316P Blood-based T cell profiling forecast ICI response in early triple-negative breast cancer (eTNBC): Preliminary data from IRIS study
2025
·
L. Negrini
, V. Martini
, et al.
·
Annals of Oncology
Alectinib-Related Hepatic Toxicity in A patient with Advanced ALK-Positive Non-Small-Cell Lung Cancer
2025
·
Beatrice Ruffilli
·
Journal of Clinical Research and Reports
PDF
Abstract P1-04-10: Peripheral blood cells as predictors of immune-related toxicity in early triple negative breast cancer (eTNBC)
2025
·
Benedetta Conte
, Beatrice Ruffilli
, et al.
·
Clinical Cancer Research
Abstract P3-12-18: NEOMET: A phase II randomized trial to evaluate the impact of “targeted” nutritional support and exercise on modulation of metabolic and immune-related markers in early breast cancer (eBC) patients candidate to neoadjuvant therapy (NAT)
2025
·
Ida Taglialatela
, Benedetta Conte
, et al.
·
Clinical Cancer Research
Abstract P2-11-09: Adding Carboplatin to neoadjuvant chemotherapy (NACT) in early triple-negative breast cancer (eTNBC): a systematic review and meta-analysis
2025
·
Beatrice Ruffilli
, Ida Taglialatela
, et al.
·
Clinical Cancer Research
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.
2024
·
Rahma Ben Ayed
, Benedetta Conte
, et al.
·
Journal of Clinical Oncology
26P Lipidic and T cell characterization as prognostic biomarkers for patients with ER+ HER2- metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK4/6i)
2024
·
L. Negrini
, B. Conte
, et al.
·
ESMO Open
PDF
Metabolomic profile as a biomarker in early breast cancer patients candidate to neoadjuvant therapy
2024
·
V. Martini
, B. Ruffilli
, et al.
·
European Journal of Cancer
PDF
290P Metabolomic profiling and response to neoadjuvant therapy (NAT) in early breast cancer (EBC)
2023
·
A. Gennari
, E. Barberis
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
27
Citation count:
78
H-index:
3
I10-index:
3
Year
Topic
Type